Idelalisib CAL 101

Idelalisib CAL 101 Market Outlook

The global Idelalisib CAL 101 market is projected to reach approximately USD 2.1 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of about 10.5% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of hematological malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), which have seen a significant rise globally. Furthermore, the growing emphasis on targeted therapies and advancements in biopharmaceutical research are contributing substantially to market expansion. The rising patient awareness regarding treatment options and the increasing investments in healthcare infrastructure are also playing pivotal roles in enhancing the accessibility and affordability of Idelalisib CAL 101 products. Additionally, the ongoing research initiatives aimed at improving the efficacy and safety profiles of Idelalisib formulations are expected to further bolster market growth in the coming years.

Growth Factor of the Market

The Idelalisib CAL 101 market is experiencing significant growth due to several key factors that are shaping its expansion trajectory. First and foremost, the rising incidence rates of chronic lymphocytic leukemia and non-Hodgkin lymphoma are driving the demand for effective treatment options. As more patients are diagnosed with these conditions, the urgency for innovative therapies such as Idelalisib becomes more pronounced. Furthermore, the growing awareness and acceptance of targeted therapies within the medical community are facilitating the adoption of Idelalisib CAL 101 among healthcare professionals. This is coupled with an increasing number of clinical trials demonstrating its efficacy, thereby building confidence among both clinicians and patients. Additionally, the favorable regulatory environment and expedited drug approval processes for promising oncology therapies are enhancing market opportunities, allowing for quicker access to treatment solutions. The emphasis on combination therapies, where Idelalisib is used alongside other agents, is also emerging as a powerful strategy to improve patient outcomes, thus contributing further to market growth.

Key Highlights of the Market

• The Idelalisib CAL 101 market is projected to grow at a CAGR of 10.5% from 2025 to 2035.
• Increased incidence of chronic lymphocytic leukemia and non-Hodgkin lymphoma drives demand.
• Growing acceptance of targeted therapies among healthcare professionals enhances adoption.
• Favorable regulatory frameworks expedite drug approvals, increasing market accessibility.
• Combination therapies are being explored to improve treatment efficacy and patient outcomes.

By Product Type

Tablet :

Tablets of Idelalisib are among the most commonly prescribed formulations due to their ease of administration and patient compliance. They are designed to provide a stable and sustained release of the active ingredient, which is critical in managing chronic conditions like chronic lymphocytic leukemia (CLL). The tablet form allows patients to follow a simple oral regimen, which is highly preferable for those managing ongoing treatment plans. Moreover, the manufacturing process for tablets is well-established, ensuring consistency in quality and dosage. The convenience of tablets not only enhances patient adherence but also makes them a favored choice among healthcare providers when prescribing Idelalisib, thereby contributing significantly to market growth. Furthermore, ongoing research is focused on optimizing tablet formulations to improve bioavailability and minimize side effects, which is expected to further boost their popularity.

Capsule :

Capsules are another popular delivery form for Idelalisib, often chosen for their potential to mask the taste and odor of the active ingredients, thus enhancing patient experience. The encapsulation process allows for the combination of multiple ingredients, which may improve the pharmacological profile of the drug. Furthermore, capsules can be designed for controlled release, ensuring that the drug is released gradually over time, leading to improved therapeutic outcomes. Pharmaceutical companies are increasingly investing in the development of capsule formulations that provide enhanced stability and bioavailability of Idelalisib. Additionally, the flexibility in capsule size and composition allows for tailored solutions that meet the diverse needs of patients, making capsules an essential segment within the Idelalisib CAL 101 market.

Injection :

Injectable forms of Idelalisib are crucial for patients who may have difficulty swallowing pills or capsules, ensuring that those in need have access to this vital treatment option. The injection route provides rapid onset of action, which can be critical in managing acute symptoms associated with hematological malignancies. As pharmacokinetics differ between oral and injectable formulations, healthcare providers may opt for injections in specific clinical scenarios where immediate therapeutic effects are necessary. Moreover, the sterile formulation of injectable Idelalisib is designed to meet stringent safety and quality standards, thus instilling confidence in both patients and healthcare professionals. The development of pre-filled syringes and other user-friendly delivery systems is expected to increase patient acceptance and adherence, further driving demand within the market.

Liquid Form :

Liquid formulations of Idelalisib cater to a specialized segment of the market, providing an alternative for patients who prefer or require non-solid dosage forms. These formulations can be particularly beneficial for pediatric patients or those with swallowing difficulties. Liquid Idelalisib offers precise dosing capabilities and can be easily adjusted to meet individual patient needs, making it a versatile option for managing complex therapeutic regimens. As the demand for personalized medicine increases, liquid formulations are becoming increasingly relevant. Manufacturers are focused on improving the stability and shelf-life of liquid Idelalisib, which is essential to ensure consistent therapeutic effects. The growth in this segment reflects the broader trend towards more adaptable treatment methods that accommodate patient preferences and specific clinical requirements.

By Application

Chronic Lymphocytic Leukemia :

Chronic lymphocytic leukemia (CLL) is one of the primary applications for Idelalisib, which has been proven effective in managing this type of hematological malignancy. The increasing rates of CLL diagnosis globally, paired with a lack of curative treatment options, have led to a surge in demand for effective therapies such as Idelalisib. The drug's mechanism of action, which targets specific pathways associated with cancer cell survival and proliferation, has shown promising results in clinical trials, leading to its endorsement by various health authorities. As patient populations grow and treatment guidelines evolve to incorporate targeted therapies, Idelalisib's role in CLL management is becoming increasingly significant. The focus on personalized medicine and tailored treatment plans is further enhancing the relevance of Idelalisib in addressing the needs of patients with CLL.

Non-Hodgkin Lymphoma :

Idelalisib is also indicated for the treatment of non-Hodgkin lymphoma (NHL), where its efficacy in targeting specific malignancies has gained considerable recognition. The rising prevalence of NHL, coupled with a growing understanding of the disease's complexities, has driven research and development efforts towards improving treatment options. Idelalisib's unique mechanism allows for a targeted approach that not only alleviates symptoms but also aims to prolong remission periods for patients. The increasing number of clinical trials exploring Idelalisib's use in various NHL subtypes indicates a robust commitment to enhancing treatment outcomes. Additionally, the integration of Idelalisib into combination therapies has expanded its application in the management of NHL, reflecting an adaptive approach to patient care that is gaining traction within the oncology community.

Small Lymphocytic Lymphoma :

Small lymphocytic lymphoma (SLL) represents another critical application for Idelalisib, with the drug providing significant therapeutic benefits. SLL is often considered synonymous with CLL, yet it requires a nuanced approach to treatment given its unique clinical presentation. Idelalisib's ability to inhibit specific signaling pathways in cancer cells makes it an essential tool in the clinician's arsenal for managing this condition. The growing body of evidence supporting the use of Idelalisib in SLL has led to its inclusion in treatment protocols and clinical guidelines, further cementing its role in the therapeutic landscape. As researchers continue to explore novel applications and combinations involving Idelalisib, its relevance in treating SLL is expected to grow, aligning with the broader trends towards precision medicine in oncology.

By Distribution Channel

Hospitals :

The hospital distribution channel plays a pivotal role in the Idelalisib CAL 101 market, as these healthcare institutions are often the primary settings for administration of specialty drugs. Hospitals are equipped with the necessary resources and expertise to manage complex treatment regimens, making them critical points of care for patients diagnosed with chronic lymphocytic leukemia and non-Hodgkin lymphoma. The presence of oncologists and hematologists within hospitals facilitates the coordinated care required for administering Idelalisib and monitoring patient responses. Furthermore, hospitals typically have established protocols for ensuring the proper storage and handling of sensitive medications, which is essential for maintaining drug efficacy. As the demand for targeted therapies continues to rise, hospital pharmacies are likely to expand their offerings of Idelalisib, contributing to the overall growth of this distribution channel.

Retail Pharmacies :

Retail pharmacies serve as important access points for patients requiring Idelalisib, providing convenience and accessibility for those prescribed the medication. As patients transition from hospital care to outpatient management, retail pharmacies play a critical role in facilitating the continuum of care. These pharmacies are increasingly stocking specialty medications, including Idelalisib, to meet the diverse needs of their patients. Additionally, retail pharmacies often provide counseling and education to patients regarding their medications, enhancing compliance and adherence to treatment regimens. The growing trend of managing chronic conditions in outpatient settings is expected to further drive the demand for Idelalisib through retail pharmacies, particularly as healthcare systems aim to optimize patient experience and outcomes.

Online Pharmacies :

The emergence of online pharmacies has transformed the way patients access Idelalisib, offering an alternative route for obtaining medications. The convenience and accessibility of online pharmacies are particularly beneficial for patients living in remote areas or those with mobility challenges. These platforms often provide competitive pricing, which can enhance affordability and accessibility to Idelalisib. Furthermore, the digital transformation in healthcare has led to increased awareness and acceptance of online medication purchases, particularly amid the ongoing emphasis on telemedicine and remote healthcare services. As regulatory frameworks evolve to support online pharmacy operations, the segment is expected to witness significant growth, providing patients with greater flexibility and convenience in managing their health.

By Ingredient Type

Idelalisib :

Idelalisib, the active pharmaceutical ingredient (API) in Idelalisib CAL 101, is a potent inhibitor of the PI3K delta pathway, playing a crucial role in the management of hematological malignancies. The specificity of Idelalisib in targeting cancerous cells while sparing normal cells has made it a vital component in treatment regimens for chronic lymphocytic leukemia and non-Hodgkin lymphoma. With a growing body of clinical evidence supporting its efficacy, the demand for Idelalisib is on the rise. As pharmaceutical companies continue to invest in research and development aimed at enhancing the formulation and bioavailability of Idelalisib, its significance in oncology will only increase. Furthermore, ongoing studies exploring combination therapies that incorporate Idelalisib may result in novel therapeutic approaches, thus expanding its application and driving market growth.

CAL-101 :

CAL-101 is a formulation that contains Idelalisib as its active ingredient, specifically designed to maximize therapeutic efficacy in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders. As a branded formulation, CAL-101 benefits from brand recognition and established clinical protocols that enhance its adoption among healthcare providers. The formulation of CAL-101 is optimized for patient compliance, offering a reliable option for those requiring continuous treatment. Additionally, ongoing research into CAL-101’s pharmacodynamics and long-term safety profiles is essential for validating its use in clinical practice. The market for CAL-101 is expected to grow as awareness of its benefits spreads within the oncology community, particularly as treatment guidelines evolve to incorporate targeted therapies.

By Region

North America has been identified as the leading region in the Idelalisib CAL 101 market, accounting for over 40% of the global market share in 2023. This dominance can be attributed to the high prevalence of hematological malignancies in the region, alongside the presence of advanced healthcare infrastructure and a strong emphasis on research and development. The United States, in particular, has a well-established regulatory environment that facilitates the rapid approval of new oncology treatments, thereby enhancing patient access to Idelalisib. Moreover, the robust presence of key pharmaceutical players in North America is expected to drive continued innovation and expansion in this market segment. With a projected CAGR of 11% during the forecast period, North America is poised for sustained growth, reflecting the ongoing commitment to improving patient outcomes in oncology.

In Europe, the Idelalisib CAL 101 market is also on a growth trajectory, with a significant increase in the adoption of targeted therapies among healthcare professionals. The European market is projected to account for approximately 30% of the global share, driven by rising awareness of hematological malignancies and advancements in treatment protocols. The European Medicines Agency (EMA) has been proactive in approving new treatments, facilitating faster access to Idelalisib for patients across member states. With a CAGR of 9.5% anticipated over the forecast period, the European market is expected to benefit from the continuous evolution of treatment guidelines that increasingly favor targeted therapies. As healthcare systems in Europe continue to emphasize personalized medicine, the role of Idelalisib in managing chronic lymphocytic leukemia and non-Hodgkin lymphoma is expected to expand significantly.

Opportunities

The Idelalisib CAL 101 market presents numerous opportunities, particularly in the context of ongoing research and development aimed at enhancing treatment efficacy and patient outcomes. One prominent opportunity lies in the exploration of combination therapies involving Idelalisib, which have the potential to improve overall response rates and prolong remission in patients diagnosed with chronic lymphocytic leukemia and non-Hodgkin lymphoma. As healthcare providers increasingly adopt a multi-faceted approach to cancer treatment, the integration of Idelalisib into combination regimens can attract further investment and attention from pharmaceutical companies, ultimately leading to expanded market presence. Additionally, the growing trend towards personalized medicine creates a conducive environment for developing tailored therapies that leverage Idelalisib’s unique properties, presenting a significant opportunity for companies to differentiate their offerings and enhance patient care.

Furthermore, expanding access to Idelalisib in emerging markets presents a substantial opportunity for growth. As healthcare systems in regions such as Asia Pacific and Latin America continue to evolve and improve, the demand for effective cancer therapies is expected to rise. There is an increasing focus on improving treatment accessibility and affordability, creating a favorable environment for the introduction of Idelalisib CAL 101 products in these markets. Collaboration with local healthcare providers, along with targeted marketing strategies, can facilitate the establishment of Idelalisib as a preferred treatment option in these regions. As awareness of hematological malignancies grows and healthcare infrastructures improve, the global footprint of Idelalisib CAL 101 is likely to broaden significantly.

Threats

One of the primary threats to the Idelalisib CAL 101 market is the potential for intense competition from other emerging therapies targeting similar pathways in the treatment of hematological malignancies. The rapid pace of innovation in oncology means that new drugs are continually entering the market, some of which may demonstrate greater efficacy or fewer side effects compared to Idelalisib. The arrival of biosimilars and alternative targeted therapies poses a risk to market share and pricing strategies for Idelalisib. Consequently, companies may need to invest heavily in marketing and research and development to maintain their competitive edge and ensure the continued success of Idelalisib in a crowded marketplace. Additionally, changes in treatment guidelines and evolving clinical practices may influence the positioning of Idelalisib relative to its competitors, necessitating a proactive approach to adapt to dynamic market conditions.

Another significant restraining factor for the Idelalisib CAL 101 market is the potential for adverse side effects associated with its use. While Idelalisib has shown effectiveness in treating chronic lymphocytic leukemia and non-Hodgkin lymphoma, some patients may experience severe adverse events that could limit their willingness to continue treatment. These side effects may include liver dysfunction and gastrointestinal issues, which can lead to treatment discontinuation and impact overall patient outcomes. Furthermore, the presence of comorbid conditions in cancer patients can complicate treatment regimens and introduce additional risks. As patient safety remains a top priority, the market must address these concerns through ongoing monitoring and research focused on improving the safety profile of Idelalisib. This includes the exploration of companion diagnostics to better predict patient responses and minimize adverse effects.

Competitor Outlook

• Gilead Sciences, Inc.
• Roche Holding AG
• Pfizer Inc.
• AbbVie Inc.
• Novartis International AG
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals, Inc.
• Celgene Corporation
• Amgen Inc.
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Incyte Corporation
• Genentech, Inc.
• Takeda Pharmaceutical Company Limited

The competitive landscape of the Idelalisib CAL 101 market is characterized by the presence of several major players who are actively engaged in the research, development, and commercialization of targeted therapies for hematological malignancies. Gilead Sciences, Inc. stands out as a frontrunner, having pioneered the development of Idelalisib and successfully positioned it as a leading treatment option for chronic lymphocytic leukemia and non-Hodgkin lymphoma. The company’s commitment to innovation is evident in its ongoing research focused on new formulations and combination therapies that leverage Idelalisib's unique mechanism of action. Additionally, Gilead's strong market presence and established distribution channels have enabled it to maintain a competitive edge in the oncology space.

Roche Holding AG is another key player within the Idelalisib CAL 101 market, known for its robust portfolio of oncology products. The company’s focus on targeted therapies aligns with the increasing demand for personalized medicine in cancer treatment. Through strategic collaborations and partnerships with research institutions, Roche aims to enhance its offerings and expand its pipeline of innovative therapies. Pfizer Inc. and AbbVie Inc. are also notable competitors, both actively pursuing advancements in hematological malignancies through their extensive research initiatives. These companies continue to invest significantly in clinical trials to optimize treatment regimens and explore novel drug combinations, ultimately elevating the competitive intensity within the market.

Novartis International AG and AstraZeneca PLC are also noteworthy participants in the Idelalisib CAL 101 market, leveraging their substantial resources to develop innovative therapies targeting similar pathways. Both companies have made significant investments in oncology research, focusing on improving patient outcomes and exploring new indications for their products. The competitive landscape is further enriched by the presence of emerging biotech companies, which are introducing new therapies and treatment modalities that challenge established players. As the market evolves, the dynamics of competition will be shaped by ongoing innovations, regulatory changes, and the shifting preferences of healthcare providers and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AstraZeneca PLC
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Genentech, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co., Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Incyte Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Celgene Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Novartis International AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Janssen Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Idelalisib CAL 101 Market, By Application
    • 6.1.1 Chronic Lymphocytic Leukemia
    • 6.1.2 Non-Hodgkin Lymphoma
    • 6.1.3 Small Lymphocytic Lymphoma
  • 6.2 Idelalisib CAL 101 Market, By Product Type
    • 6.2.1 Tablet
    • 6.2.2 Capsule
    • 6.2.3 Injection
    • 6.2.4 Liquid Form
  • 6.3 Idelalisib CAL 101 Market, By Ingredient Type
    • 6.3.1 Idelalisib
    • 6.3.2 CAL-101
  • 6.4 Idelalisib CAL 101 Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Idelalisib CAL 101 Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Idelalisib CAL 101 market is categorized based on

By Product Type

• Tablet
• Capsule
• Injection
• Liquid Form

By Application

• Chronic Lymphocytic Leukemia
• Non-Hodgkin Lymphoma
• Small Lymphocytic Lymphoma

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Idelalisib
• CAL-101

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Gilead Sciences, Inc.
• Roche Holding AG
• Pfizer Inc.
• AbbVie Inc.
• Novartis International AG
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceuticals, Inc.
• Celgene Corporation
• Amgen Inc.
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Incyte Corporation
• Genentech, Inc.
• Takeda Pharmaceutical Company Limited